Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaccination response after rituximab-containing therapy in lymphoma
NL-OMON27098Withdrawn
- Sponsor
- St. Antonius Ziekenhuis
- Start
- Jun 2012
- Modality
- Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Randomised, open-label trial of Prevnar 13, Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen and 23-valent pneumococcal polysaccharide vaccine in pneumococcal disease and Haemophilus influenzae type b disease (Hib), sponsored by St. Antonius Ziekenhuis. Primary endpoint: Antibody response to pneumococcal and Hib vaccination. Planned start Jun 2012; status: withdrawn.
02
Drugs
Prevnar 13Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen23-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumococcal diseaseHaemophilus influenzae type b disease (Hib)
Beyond the preview
Go deeper on NL-OMON27098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27098.